S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
Log in

NASDAQ:ANIKAnika Therapeutics Stock Price, Forecast & News

$28.17
-0.92 (-3.16 %)
(As of 04/7/2020 03:08 PM ET)
Add
Compare
Today's Range
$28.10
Now: $28.17
$30.82
50-Day Range
$22.38
MA: $35.04
$43.06
52-Week Range
$22.01
Now: $28.17
$75.71
Volume7,141 shs
Average Volume226,683 shs
Market Capitalization$399.17 million
P/E Ratio14.83
Dividend YieldN/A
Beta1.17
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More
Anika Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.51 million
Cash Flow$2.54 per share
Book Value$20.21 per share

Profitability

Net Income$27.19 million

Miscellaneous

Employees133
Market Cap$399.17 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.


Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK shares have decreased by 22.6% and is now trading at $28.17. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Anika Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Anika Therapeutics.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Anika Therapeutics.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, February, 20th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.02. The biotechnology company had revenue of $29.77 million for the quarter, compared to analyst estimates of $27.63 million. Anika Therapeutics had a net margin of 23.73% and a return on equity of 10.81%. View Anika Therapeutics' earnings history.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160-165 million, compared to the consensus revenue estimate of $138.97 million.

What price target have analysts set for ANIK?

4 brokerages have issued 12-month price objectives for Anika Therapeutics' stock. Their forecasts range from $29.00 to $65.00. On average, they expect Anika Therapeutics' stock price to reach $53.75 in the next year. This suggests a possible upside of 90.8% from the stock's current price. View analysts' price targets for Anika Therapeutics.

What are Wall Street analysts saying about Anika Therapeutics stock?

Here are some recent quotes from research analysts about Anika Therapeutics stock:
  • 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (2/24/2020)
  • 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019)

Has Anika Therapeutics been receiving favorable news coverage?

Media headlines about ANIK stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAnika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Gilead Sciences (GILD), Celgene (CELG), CVS Health (CVS), AT&T (T), Broadcom (AVGO), Ligand Pharmaceuticals (LGND), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Amgen (AMGN).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
  • Mr. Alexei Goraltchouk, VP of Operations

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View institutional ownership trends for Anika Therapeutics.

Which major investors are buying Anika Therapeutics stock?

ANIK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $28.17.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $399.17 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe. View additional information about Anika Therapeutics.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel